Nucana Plc (NCNA)
NASDAQ:NCNA
Want to see NCNA full AI Analyst Report?
NCNA Stock Chart & Stats
$3.33
-$0.06(-4.88%)
At close: 4:00 PM EST
$3.33
-$0.06(-4.88%)
Day’s Range― - ―
52-Week Range$1.33 - $250.00
Previous CloseN/A
Volume88.96K
Average Volume (3M)174.33K
Market Cap
$9.07M
Enterprise Value-$13.97M
Total Cash (Recent Filing)$24.21M
Total Debt (Recent Filing)$674.81K
Price to Earnings (P/E)―
Beta1.57
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding4,161,971
10 Day Avg. Volume84,221
30 Day Avg. Volume174,327
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.41
Price to Sales (P/S)0.00
P/FCF Ratio-1.42
Enterprise Value/Market Cap-1.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit205.07
Enterprise Value/Ebitda0.68
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Minimal DebtVery low debt materially reduces financial risk and preserves strategic optionality. For a clinical-stage biotech, minimal leverage lowers default risk during multi-year development timelines and makes equity financings and partnerships easier to negotiate, supporting sustainable R&D execution.
NUC-7738 Clinical Progress And Regulatory IntentPositive Phase 2 activity plus active pursuit of FDA guidance represents structural de-risking of the lead program. A defined registrational path can convert clinical progress into a regulatory strategy and eventual commercialization, materially improving the company's long-term revenue and partnering prospects.
Cash Runway Into 2029 After FinancingsAn extended cash runway through 2029 provides durable operational continuity and reduces near-term dilution risk, allowing management to advance clinical milestones and seek higher-value partnerships or regulatory interactions before needing additional financing.
Bears Say
No Revenue; Material Net LossesAbsence of revenue and recurring large losses mean the business remains fully pre-revenue and dependent on external funding. Until a commercialized product or sustainable licensing income appears, profitability is unlikely, constraining long-term self-funding and strategic flexibility.
Persistent Cash Burn And Financing RelianceConsistent negative operating and free cash flow creates structural reliance on equity or other financing. Even with recent improvement, volatility in burn and free cash flow raises the probability of future dilutive financings, which can impede shareholder value over the medium term.
Volatile Equity Base And Dilution HistoryA history of sharp equity swings and dilution indicates prior reliance on equity raises to fund development. This precedent increases the likelihood that management will issue additional equity in the future, diluting existing holders and signaling funding vulnerability during long clinical timelines.
Nucana News
NCNA FAQ
What was Nucana Plc’s price range in the past 12 months?
Nucana Plc lowest stock price was $1.33 and its highest was $250.00 in the past 12 months.
What is Nucana Plc’s market cap?
Nucana Plc’s market cap is $9.07M.
When is Nucana Plc’s upcoming earnings report date?
Nucana Plc’s upcoming earnings report date is May 14, 2026 which is in 26 days.
How were Nucana Plc’s earnings last quarter?
Nucana Plc released its earnings results on Mar 19, 2026. The company reported $0 earnings per share for the quarter, the consensus estimate of N/A by $0.
Is Nucana Plc overvalued?
According to Wall Street analysts Nucana Plc’s price is currently Overvalued.
Does Nucana Plc pay dividends?
Nucana Plc does not currently pay dividends.
What is Nucana Plc’s EPS estimate?
Nucana Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nucana Plc have?
Nucana Plc has 4,161,971 shares outstanding.
What happened to Nucana Plc’s price movement after its last earnings report?
Nucana Plc reported an EPS of $0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -3.509%.
Which hedge fund is a major shareholder of Nucana Plc?
Currently, no hedge funds are holding shares in NCNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nucana Plc
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Technical Analysis
Ownership Overview
―
Insiders
8.30% Other Institutional Investors
91.70% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---